| Detected | Trial | Change |
|---|---|---|
| 2026-05-23 | NCT07349069 A Phase III Trial Comparing HRS-8080 With Standard Endocrine Therapy in Patients With… |
Enrollment increased: 4800 -> 5500 participants |
| NCT ID | Title | Condition | Status |
|---|---|---|---|
| Phase 3 | |||
| NCT07024173 | A Phase 3 Study of HRS-8080 Versus Treatment Chosen by Physicians in Locally Advanced and… | Locally Advanced Breast Cancer | Recruiting |
| NCT07349069 | A Phase III Trial Comparing HRS-8080 With Standard Endocrine Therapy in Patients With… | Breast Cancer | Recruiting |
| NCT05645536 | Safety Extension Study for Subjects With HR+, HER2- Breast Cancer for Subjects Who Have… | Breast Cancer | Enrolling by Invitation |
| NCT04906395 | Ovarian Suppression Evaluating Subcutaneous Leuprolide Acetate in Breast Cancer | Breast Cancer | Active, Not Recruiting |
| Phase 1/2 | |||
| NCT06974929 | A Clinical Study of HRS-6209 Combined With Other Treatment Regimens in Patients With… | Breast Cancer | Recruiting |
| NCT07389733 | A Study of HRS-6208 in Combination With HRS-8080, or Fulvestrant, or Letrozole, With or… | Advanced Unresectable or Metastatic Breast Cancer of Adults | Recruiting |